Content available at: https://www.ipinnovative.com/open-access-journals

IP International Journal of Comprehensive and Advanced Pharmacology

Journal homepage: www.ijcap.in

Short Communication

A short communication on digital and smart pharmacology: A new frontier in personalized medicine

Shivam Dubey[1*]

[1]Rani Durgavati Vishwavidyalaya, Jabalpur, Madhya Pradesh, India

Abstract

Digital and smart pharmacology is redefining the landscape of healthcare by integrating information technology, artificial intelligence, and biomedical sensors into pharmacological processes. These advancements enhance drug adherence, optimize dosage regimens, and facilitate real-time therapeutic monitoring. This review outlines the current state of digital pharmacology, focusing on digital pills, wearable biosensors, mobile health applications, and AI-driven drug management. While the field presents vast opportunities for precision medicine, challenges such as data privacy, regulatory hurdles, and technology accessibility must be addressed for widespread adoption.

Keywords: Digital pharmacology, Smart drug delivery, Personalized medicine, Digital therapeutics, Artificial intelligence in healthcare, Wearable biosensors.

Received: 02-06-2025; **Accepted:** 05-07-2025; **Available Online**: 23-07-2025

1. Introduction

Pharmacology, traditionally rooted in molecular and physiological sciences, is undergoing a digital transformation. The integration of digital tools into pharmacological care—termed digital and smart pharmacology—is shifting the paradigm from a reactive to a proactive approach in drug therapy. This evolution is propelled by the growing need for personalized medicine, improved medication adherence, and more accurate monitoring of treatment outcomes.[1] Global patient care might be revolutionized by the digitalization of the healthcare industry. From bettering real-time diagnoses and treatments to increasing access to physicians and medications, virtual tools such as artificial intelligence, blockchain, virtual reality, and augmented reality, to mention a few, are offering substantial advantages to both patients and the pharmaceutical industry. To build a comprehensive cyber healthcare system, it is indeed envisaged that these technologies would interact with one another in real time as well as with their physical equivalents. This overview examines current developments and potential paths forward in this quickly changing subject.

2. Discussion

The integration of cutting-edge technology like blockchain and artificial intelligence is driving the digital revolution in the pharmaceutical sector, which is drastically changing the way healthcare is delivered. With an estimated 14.42% annual growth rate, the digital pharmacy industry is expected to develop significantly throughout this transition, reaching a market size of over $35.33 billion by 2026. The COVID-19 pandemic has had a significant impact on the increasing reliance on online pharmacy platforms, which is one significant part of this shift. The rise in consumer confidence in online drug purchases suggests a move toward digital healthcare solutions. In the United States, patient use of telehealth services, including tele pharmacy, has increased dramatically, rising from 11% in 2019 to 46%. Although this move to digital-first services improves accessibility and convenience, it also presents regulatory problems, especially

*Corresponding author: Shivam Dubey
Email: shivamdubey20@gmail.com

https://doi.org/10.18231/j.ijcaap.2025.017

when it comes to upholding patient safety and quality standards in the ever-changing online healthcare landscape.

Pharmacy education platforms have changed in tandem with practice developments, particularly as a result of the pandemic. Traditional and student-centered teaching approaches, such as online didactic lectures and in-person experiential training, have been combined in these platforms. The use of blended learning strategies, which mix online lectures with in-person lab sessions, is indicative of a larger movement in education toward hybrid models. By combining the benefits of online and conventional teaching approaches, this strategy seeks to provide a more adaptable and maybe more successful learning environment.[2]

Integrating educational technology into pharmacy education involves more than simply putting new tools into place; it also entails comprehending how these technologies impact instruction and student learning. Their use needs to be purposeful in order to enhance the educational process. Systematic assessments of the impact of new technologies on undergraduate pharmacy teaching and learning have demonstrated the growing scientific interest in this area.[3] To shape the profession and ensure that pharmacists are prepared to meet the constantly evolving needs of the healthcare system, these digital platforms are likely to play an increasingly important role in pharmacy education in the future. This change reflects a broader movement in the healthcare sector toward a more adaptable, patient-centered, and technologically sophisticated setting.[4]

A new era in pharmaceutical treatment and management is being ushered in by technological advancements. AI is also used in retail pharmacies for inventory management, where it forecasts patient demands and improves supply chain effectiveness. Blockchain technology legitimizes medical goods and improves supply chain transparency, which is particularly important in regions where counterfeit medications are prevalent. Additionally, blockchain is essential to telemonitoring systems and patient-centered electronic health records. One example of the notable improvements in healthcare accessibility and pharmacy service delivery is PharmaGo, a cutting-edge platform created in response to the pandemic that offers a full online pharmaceutical service. Below is a summary of a few instances of technological advancements:

1. Ingestable sensors and digital pills an innovative advancement in medication monitoring is represented by digital pills. These are conventional capsules that have ingestible sensors built into them that react when they come into touch with stomach contents. Following ingestion, the pill signals a wearable patch, which relays the information to a cloud platform or mobile device.[5] One well-known example is the Proteus discover system, which is intended to track adherence in patients with severe mental disorders or long-term medical diseases like diabetes and hypertension. The approach is now being advanced by several startups. Digital tablets have been investigated for ailments like cardiovascular disease, schizophrenia, and TB.
2. Wearable Technology and Remote Drug Monitoring: Wearable technology, including glucose monitors, biosensor patches, and smartwatches, allows for the real-time monitoring of physiological data that are pertinent to pharmacological reactions. These consist of blood glucose, respiration, heart rate, and medication concentrations. Pharmacology and digital technology come together in devices like smart insulin pens and continuous glucose monitoring (CGMs). These devices lessen hypoglycemia episodes, enhance glycemic control, and provide dynamic insulin dosage.[6] Additionally, it makes remote monitoring possible, which lessens the need for frequent clinic visits, allows for the early detection of adverse medication responses, and promotes a more responsive healthcare system—all of which are crucial in settings with limited resources or in rural areas.[7]
3. AI and Big Data in Pharmacology: The processing of the enormous amounts of data produced by digital health devices depends heavily on artificial intelligence (AI) and machine learning (ML). These technologies are used to detect early indications of medication toxicity or ineffectiveness, improve dose schedules, forecast drug interactions, and customize treatment based on patient biometrics. Adaptive dosing algorithms, which modify medication doses in response to patient reaction, have also been made possible by artificial intelligence (AI), which minimizes trial-and-error in drug delivery.[8]
4. Mobile Health (mHealth) Apps: These apps give users the ability to track side effects, manage their meds, get reminders, and access teleconsultations. These applications increase adherence and give doctors the ability to monitor drug-related behavioural trends. Electronic Health Records (EHRs) and advanced mHealth platforms are now seamlessly integrated, facilitating information flow that supports treatment planning, adverse event reporting, and medication reconciliation.

3. Benefits of Digital Pharmacology

1. One benefit of digital pharmacology is increased adherence, which is achieved by digital tablets and reminders.
2. Customized dosing: AI and sensors enable customized treatment plans.
3. Real-time pharmacovigilance: AI makes it possible to identify adverse drug reactions (ADRs) in real-time by mining vast amounts of data from wearable technology, social media, and electronic health records. By identifying signals from unstructured data sources, natural language processing (NLP)

approaches improve patient safety.[9] These methods are particularly important for post-market monitoring of novel medications and vaccines.

4. Accessibility to remote care: Enables treatment in isolated or underprivileged areas.
5. Data-driven decision-making: Provides physicians with useful information.
6. Behavioral and cognitive assistance: Through gamification, AI chatbots, and mental health modules, mHealth systems provide cognitive behavioral assistance in addition to managing physical symptoms. Apps such as reSET-O and Woebot have shown promise in treating opioid use disorder and depression, respectively.[10,11]
7. Economic and Environmental Benefits: By reducing hospital stays, preventing needless prescriptions, and encouraging preventative care, digital pharmacology can save healthcare expenses. Additionally, intelligent medication delivery systems can reduce environmental pollution and drug waste.[12]
8. Synergies with telemedicine and digital twins: A new era of predictive and preventive pharmacotherapy may be ushered in by the growing integration of digital pharmacology with telemedicine platforms and the new idea of "digital twins"—virtual simulations of individual patients that aid in predicting treatment outcomes prior to drug administration.[13]

4. Problems and Ethical Issues

Although virtual-based digital health technologies can greatly improve patient care, there are still several issues that need to be resolved, from data security to acceptance in the medical community. Digital pharmacology has several drawbacks despite its advantages:

1. Data privacy: Constant data transfer raises questions about patient privacy and abuse.[1]
2. Regulatory oversight: Digital drug delivery and monitoring platforms do not meet consistent criteria.
3. Technological inequality: There is still disparity in access to smart gadgets and internet connectivity worldwide.
4. Patient acceptance: Adoption may be hampered by patients' resistance to intrusive or strange technology.
5. To preserve public confidence, ethical concerns about algorithmic transparency, data ownership, and permission must be addressed.
6. Continuous trials and regulatory approvals in addition to Abilify MyCite, a few digital pharmaceutical items are undergoing clinical testing. Otsuka and click therapeutics, for example, have created a computerized treatment (CT-152) that targets major depressive illness and is presently undergoing Phase III studies.[14] To categorize and track these digital tools as either combination goods or software as a medical device (SaMD), regulatory bodies such as the FDA and EMA are creating frameworks. A key player in this development has been the FDA's Digital Health Center of Excellence.[15]

5. Prospects

Outlook for the future pharmacology will become more and more computerized in the future. The way medications are given, dispensed, and tracked will be further revolutionized by emerging technologies including blockchain-based drug tracking systems, smart drug patches, and nano biosensors. It will be crucial to include digital pharmacology into routine clinical practice as telemedicine grows.

6. Conclusion

In contemporary medicine, digital and smart pharmacology is a revolutionary force. It provides previously unheard-of chances to improve clinical outcomes, personalize therapy, and increase medication adherence by fusing pharmacology with state-of-the-art digital technologies. To fully realize its potential, interdisciplinary cooperation, patient-centered methods, and strategic policy development are essential. These technology developments play a key role in enhancing healthcare professionals' teamwork and data sharing. Through data analytics, they provide tremendous promise for individualized therapy and are essential for patient involvement and health self-management. Future developments in the pharmaceutical industry point to a move toward Pharmaceutical Digital Marketing (PDM) and a more customer-centric strategy, which has been especially impacted by the COVID-19 pandemic. Automation of repetitive activities, individualized medication management, real-time patient data access, and the detection of trends in medication adherence and possible drug interactions are just a few of the ways artificial intelligence (AI) has the potential to completely transform the pharmacy industry.

7. Source of Funding

None.

8. Conflict of Interest

None.

References

1. Bush WS, Cooke Bailey JN, Beno MF, Crawford DC. Bridging the Gaps in personalized medicine value assessment: A review of the need for outcome metrics across stakeholders and scientific disciplines. *Public Health Genomics*. 2019;22(1-2):16–24.
2. Shawaqfeh MS, Al Bekairy AM, Al-Azayzih A, Alkatheri AA, Qandil AM, Obaidat AA, et al. Pharmacy students perceptions of their distance online learning experience during the COVID-19 pandemic: A cross-sectional survey study. *J Med Educ Curric Dev.* 2020;7:2382120520963039.
3. Lee CY, Lee SWH. REVIEW: Impact of the educational technology use in undergraduate pharmacy teaching and learning – A systematic review. *Pharm Educ*. 2021;21:159–68.
4. Strawbridge J, Hayden JC, Robson T, Flood M, Cullinan S, Lynch M, et al. Educating pharmacy students through a pandemic:

Reflecting on our COVID-19 experience. *Res Social Adm Pharm*. 2022;18(7):3204–9.
5. Serretti A. The present and future of precision medicine in psychiatry: Focus on clinical psychopharmacology of antidepressants. *Clin Psychopharmacol Neurosci.* 2018;16(1):1–6.
6. Heinemann L, Freckmann G, Ehrmann D, Faber-Heinemann G, Guerra S, Waldenmaier D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. *Lancet.* 2018;391(10128):1367–77.
7. Topol E. Deep medicine: how artificial intelligence can make healthcare human again. London: Hachette UK; 2019.
8. Yu KH, Beam AL, Kohane IS. Artificial intelligence in healthcare. *Nat Biomed Eng*. 2018;2(10):719–31.
9. Banda JM, Evans L, Vanguri RS, Tatonetti NP, Ryan PB, Shah NH. A curated and standardized adverse drug event resource to accelerate drug safety research. *Sci Data.* 2016;3:160026.
10. Fitzpatrick KK, Darcy A, Vierhile M. Delivering cognitive behavior therapy to young adults with symptoms of depression and anxiety using a fully automated conversational agent (woebot): a randomized controlled trial. *JMIR Ment Health*. 2017;4(2):e19.
11. Pear Therapeutics Inc. reSET-O: clinician directions for use [Internet]. Boston (MA): Pear Therapeutics Inc.; 2020 [cited 2025 Jul 17].
12. Benedetto V, Mainardi V, Pennucci F, Damone A, Ciuti G, Nuti S. Digital health for environmentally sustainable cancer screening. *npj Digit Med*. 2025;8. https://doi.org/10.1038/s41746-025-01561-x
13. Björnsson B, Borrebaeck C, Elander N, Gasslander T, Gawel DR, Gustafsson M, et al. Digital twins to personalize medicine. *Genome Med*. 2019;12(1):4.
14. Rothman B, Slomkowski M, Speier A, Rush AJ, Trivedi MH, Lawson E, et al. Evaluating the efficacy of a digital therapeutic (ct-152) as an adjunct to antidepressant treatment in adults with major depressive disorder: Protocol for the MIRAI remote study. *JMIR Res Protoc.* 2024;13:e56960.
15. US Food and Drug Administration. Digital Health Center of Excellence [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2025 [cited 2025 Jul 2]. Available from: https://www.fda.gov/medical-devices/digital-health-center-excellence.

Cite this article: Dubey S. A short communication on digital and smart pharmacology: A new frontier in personalized medicine. *IP Int J Compr Adv Pharmacol*. 2025;10(2):115–118.